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Breast cancer is the second most common cancer in women, after skin cancer. It is 
most commonly diagnosed in women aged 55 to 64. It is estimated that around 1.67 
million new cases of breast cancer occurred among women worldwide in 2012 (most 
recent data available) (WHO, 2012), but it doesn’t mean that it is not common among 
young women.  
Young women do not consider that they could get breast cancer in early age and 
screening program starts in Finland only at the age of 50. The purpose of this project is 
to provide young healthy women with the information about breast cancer and also give 
some hints to those who have been newly diagnosed with it. 
Breast cancer treatment is changing rapidly, including chemotherapy regimens that are 
becoming easier to tolerate, surgical procedures that are becoming less invasive, 
precise radiation treatment that is avoiding healthy organs as much as possible, 
hormonal therapy that is fighting hormone receptor-positive disease, and biological 
therapies that are targeting cancer cells. 
This project task is to create an informative web page for healthy women and those, 
diagnosed with primary breast cancer on Terveysnetti. The aim is to increase 
information about primary breast cancer prevention and treatment options. 
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disease, Woman’s disease 
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Tietoa rintasyövästä nuorille naisille 
- Projekti Terveysnettiin 
Rintasyöpä on toiseksi yleisin syöpä naisilla, ihosyövän jalkeen. Se on yleisimmin 
diagnosoitu 55 - 64 vuotiailla naisilla. On arvioitu, että noin 1,67 miljoonaa uutta 
rintasyöpätapausta diagnosoitiin naisilla maailmanlaajuisesti vuonna 2012 (tuoreimmat 
tiedot saatavilla) (WHO, 2012), mutta se ei tarkoita, että se ei ole yleistä nuorilla 
naisilla.  
Nuoret naiset eivät usko, että he voisivat saada rintasyövän varhaisessa iässä ja 
seulonta ohjelma käynnistyy Suomessa vasta 50 ikäisenä. Tämän projektin 
tarkoituksena on tarjota terveille nuorille naisille tietoa rintasyövästä ja myös antaa 
vihkkejä niille, joilla on juuri diagnosoitu se. 
Rintasyövän hoito muuttuu nopeasti, kuten solunsalpaajahoito, jota on helpompi sietää, 
kirurgiset toimenpiteet, jotka ovat vähemmän invasiivisia, tarkemmin kohdennettua 
sädehoitoa, joka välttelee terveitä elimiä mahdollisimman paljon, hormonihoito, joka 
taistelee hormonireseptoripositiivista sairautta vastaan, ja biologiset hoidot, jotka 
kohdistuvat syöpäsoluihin. 
Tämän projektin tehtävänä on luoda informatiivinen web-sivu terveille naisille ja niille, 
joilla on diagnosoitu primaarinen rintasyöpä. Tämän projektin tarkoituksena on lisätä 
naisten informaatiota primaarisen rintasyövän ennaltaehkäisemisestä ja 
hoitovaihtoehdoista. 
 
 
 
 
Asiasanat: syöpä, rintasyöpä, nuoret naiset, tieto, informatio, kasvain, syöpätaudit tauti, 
naisten taudit  
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1 INTRODUCTION   
Healthy women do not want to think about breast cancer. This is probably due 
to the fact that in the past in most cases cancer was an incurable disease and 
its detection actually meant a notice of the impending death of a person. 
However, nowadays the situation has changed.  
As statistics show, the rate of breast cancer incidents among women younger 
than 49 is 34, 5 % of all cancer cases in Nordic countries. And in Finland, it is 
37, 0% of all cancer cases. (NORDCAN, 2014.) So the rate is quite high also 
among young women and chances of getting breast cancer grow up with the 
age.  
At different points of life, many women notice in their breasts various frightening 
and unpleasant changes like compression, pain, change in shape, discharge 
from the nipples. (National Cancer Institute, 2015). Suspicion of breast cancer 
occurs in many women in connection with various symptoms and changes in 
the mammary glands. In such cases, doctors usually recommend further 
investigation. Fortunately, about 90% of women, with the further examination 
after 2 years show that a suspicious change in their breast is not cancer. 
( Løberg et al, 2015.) 
In recent years there has been a lot of research in the field of breast cancer, 
new and more effective treatments for breast cancer have been found. In lots of 
cases, breast cancer is curable and the most important factor for a full recovery 
is an early detection. 
Information collected in this thesis will help women to understand how to 
prevent and treat breast cancer at young age. It will also help them to get 
information on different existing treatment options.  
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2 BACKGROUND 
 
2.1 DEFINITION 
Breast cancer starts when cells in the breast begin to grow out of control. These 
cells usually form a tumor that can often be seen on an x-ray or felt as a lump. 
The tumor is malignant (cancerous) if the cells can grow into (invade) 
surrounding tissues or spread (metastasize) to other parts of the body.  
(American Cancer Society, 2016.) 
 
2.2 STAGES OF BREAST CANCER 
The process of determining breast cancer stage has several important 
parameters of tumor development: its size, its distribution to the surrounding 
tissue, whether it has spread to the lymph nodes in the breast or around it, 
whether it has spread to other organs. On the basis of these data, the stage is 
found out as well as a treatment strategy. The survival rate is always calculated 
based on observations of people who have been treated for cancer 5 years ago. 
(American Cancer Society, 2016.) 
 
Stage Zero of breast cancer means that breast cancer cells have developed, 
but they did not have time to spread to any surrounding tissues, or to the lymph 
nodes or other organs. Usually, zero stage means the so-called ductal 
carcinoma in situ or lobular carcinoma in situ. (National Cancer Institute, 2016.)  
 At stage 0 survival rate during 5 years is almost 100%. (American Cancer 
Society, 2016).  
 
The first stage of breast cancer means that tumor size is less than 2 cm. And 
that the tumor has not yet spread to the lymph nodes or to other organs (i.e. not 
metastasized) (Stage 1A) or was able to form only micrometastases in 1-3 
lymph nodes in the underarm area (Stage 1B). (National Cancer Institute, 
2016.)  
On the 1st stage, the survival rate during 5 years is almost 100%. (American 
Cancer Society, 2016). 
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Stage 2A indicates that tumor size is less than 2 cm (or not detected) and has 
one or both of the following characteristics: 
 Already spread to no more than 3 lymph nodes under the arm, forming 
metastases more than 2 mm in diameter; 
 Small metastases were found in the lymph nodes in mammary glands; 
OR tumor is greater than 2 cm in diameter, but less than 5 cm and has not 
spread to the lymph nodes or other organs. (Breastcancer.org, 2016.) 
 
Stage 2B indicates that tumor is greater than 2 cm in diameter, but less than 5 
cm and has not spread to the lymph nodes or other organs or small cancer 
metastases were found in no more than three lymph nodes in the axilla and / or 
lymph nodes in mammary gland, but not found in the internal organs; 
OR the tumor is larger than 5 cm in diameter, but has not grown into the chest 
wall or skin and did not form metastases in the lymph nodes or internal organs. 
(Breastcancer.org, 2016.)  
At stage 2 the survival rate during 5 years is about 93%. (American Cancer 
Society, 2016).  
 
Stage 3A indicates that tumor is not more than 5 cm across and has spread to 
no more than 9 lymph nodes in the axilla or formed metastases in the lymph 
nodes in mammary gland, but not to internal organs; 
OR the tumor is greater than 5 cm in diameter, has spread to no more than 9 of 
the lymph nodes under the arm and formed metastases in the lymph nodes in 
mammary glands, however, did not grow into the breastbone or skin and has no 
metastasis in internal organs. (National Cancer Institute, 2016.)  
 
Stage 3B means that the tumor had time to grow into the chest wall or skin, 
but did not form metastases in the internal organs and has one of the following 
characteristics found from NCI (2016): 
 no metastases in the lymph nodes; 
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 has only 1-3 micrometastases in lymph nodes or axillaries lymph nodes 
in mammary glands; 
 It does not spread to more than 9 lymph nodes in the axilla or form 
metastases in the lymph nodes inside the mammary gland.  
 
Stage 3C is a tumor, regardless of its size; it has one of the following 
characteristics, as said in NCI (2016): 
 Has metastases in more than 10 lymph nodes under the arm; 
 Has metastases in the lymph nodes under or above the collarbone.  
During the stage 3 survival rate during 5 years is approximately 72%. (American 
Cancer Society, 2016.)  
 
The fourth stage is when the tumor, regardless of its size, was able to form 
metastases in other organs. In most cases, breast cancer metastases are 
formed in bones, liver, brain or lungs. (NCI, 2016).  
Survival rate during 5 years at 4th stage is on average 22%. (ACS, 2016).  
 
2.3 SIGNS & SYMPTOMS 
The main symptoms of breast cancer collected from Cancer research UK 
(2014) and ACS (2016) may be: 
 Presence in one or both breasts of one or more ”hard masses” lumps 
of any size, shape, texture, with smooth or non-smooth edges. 
 Inflammation (redness, swelling, increase of temperature) of the entire 
breast, or some part of it. 
 Change of the skin of breast: noticeable depressions, redness, or 
thickening. 
 Prolonged pain in one or both breasts, the cause of which is not clear 
(in many cases, breast cancer develops painlessly). 
 Nipple retraction (if before the nipple was another form). 
 Redness, peeling, the appearance of sores on the nipple. 
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 Any discharge (including bleeding or transparent fluid) from the nipple, 
without a known reason. 
 For a long time (over 2 weeks) swollen lymph nodes under or above 
the clavicle or in the armpit.  
 
2.4 MAMMOGRAPHY 
There are several different treatments that can partially or completely prevent 
the development of breast cancer. They are: special drugs (Nazarali at al., 
2014), removal of parts that develop "pre-cancerous changes" and the complete 
removal of the breast. (NCI, 2013). However, this kind of preventive treatment is 
recommended mainly for women with high risk of developing breast cancer. 
For women with conventional (average) risk of developing breast cancer, such 
treatments should be avoided. After a certain age, they are only recommended 
to undergo regular special preventive screening – mammograms. In Finland, it 
is recommended to undergo mammography screening starting 50-69 y.o. 
(Finnish Cancer Registry, 2010.) 
Preventive mammography can detect breast cancer in its early stages when it 
may still have no symptoms but can be perfectly treated. Women who do 
regular mammograms have a much better chance of successful treatment and 
full recovery. In other words, regular mammogram screening can prevent the 
development of advanced cancer, for which recovery prognosis is much worse 
than in the beginning. ( Løberg et al, 2015.) 
Currently, mammography is the main cancer screening method for the breast. 
Due to the fact that this survey is relatively simple, affordable, safe, cheap, all 
the women to who it is recommended can have it. (WHO, 2016).  
Mammography is a test when several X-ray images are taken of the mammary 
glands (breasts). Mammography is performed in a specially equipped room with 
mammography machine. It is a form of an x-ray machine. Before 
mammography, it is needed to undress from the waist up. Pictures of each 
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breast are done separately. The process may take about 20 minutes. (NCI, 
2014.)  
Finland was the first country to introduce governmental screening 
mammography program in 1987. The participation rate is now about 90% of the 
targeted age group. The invitation letter is coming by post for each woman in 
Finland who turns 50 y.o.  The screening takes place every second year. 
(Finnish Cancer Registry, 2010.) 
The majority of women who undergo screening mammography the examination 
do not show any changes. Only 5-10% of women after another preventive 
mammography of the breast are detected with some changes that are difficult to 
distinguish from cancer. In such cases, doctors recommend an additional 
examination: ultrasonography and biopsy. For 90% of women that are 
prescribed with biopsy after mammography, the survey does not show any 
dangerous changes. (Yankaskas at al., 2010.)  
Women younger than 40 years who do not have a genetic predisposition to the 
development of breast cancer are not recommended to undergo preventive 
mammograms. Before the age of 40, the development of breast cancer is 
unlikely. On the other hand, it is the time (up to this age) when women develop 
some changes in the mammary glands, such as fibrocystic breast disease, 
fibroadenoma, and so forth. (Cardoso et al., 2012.)   
Only with non-hazardous mammography, these changes cannot be 
distinguished from "cancer." For obvious reasons, to find any changes that may 
be a "tumor" it is recommended to do further examinations: biopsies or even 
surgical removal of the formation in order to finally make sure that it is not 
dangerous. (Cardoso et al., 2012).   
Thus, if all women up to 40 years would regularly undergo preventive 
mammograms, many of them would have been forced to take a number of other 
(often unpleasant) and partly useless surveys, which only prove that their 
formation in the breast is not dangerous. 
12 
 
TURUN AMK:N OPINNÄYTETYÖ | Anzhelika Mitsuk  
Another reason that mammography is not recommended for women under 40 is 
the fact that before this age breast tissue is quite dense, which is why in the 
results of mammography cannot be found a lot of information (if there are some 
changes, mammography could "miss" it). (Cardoso et al., 2012.)  
2.5 CAUSES AND RISK FACTORS 
The exact causes of breast cancer are not known. A significant role in the 
development of this disease may play age, genetic predisposition, female sex 
hormones, however, it is still not clear exactly how all of these factors contribute 
to the growth of the tumor. (Hashemi et al 2014.) 
Development of breast cancer has nothing to do with the size of the breast, 
wearing a bra, using deodorants (antiperspirants), or abortion. 
(Breastcancer.org, 2015).  
Breast implants (artificial breast) do not have a carcinogenic effect. However, in 
women undergoing surgery for breast augmentation or correction of breast 
shape, the probability of developing cancer may be slightly higher than average 
due to the fact that during the operation in the breast tissue may remain small 
scars (in scars cell growth may change ). (McLaughlin at al., 2006).  
Injuries of the breast (punches) also may slightly increase the likelihood of 
developing cancer due to scarring. (Cancer Research UK, 2014).  
Receiving oral contraceptives slightly increase the risk of breast cancer, but the 
risk is returning to the average level after a woman stops taking the medication. 
(Beaber et al., 2014). 
Smoking may contribute to the development of mammary gland cancer in 
women with long experience of heavy smoking. (Hashemi et al 2014). 
One of the problems connected with breast cancer is the fact that women often 
do not have a proper idea of how great the risk of developing the disease they 
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have, and that the likelihood of developing the disease increases with age. 
(Mintzer et al., 2002).  
Modern statistical studies in the US show that the average chance of 
developing breast cancer in all women throughout their life is about 12%. This 
means that out of 100 women breast cancer eventually develops in about 12-13 
women. (Breastcancer.org, 2016.)  
Obviously, this is a very high figure, but distribution by age is extremely uneven. 
During the research, it was found that the risk of breast cancer in young women 
is very small. On the other hand, older women (over 40 y.o.) and particularly in 
elderly women risk of developing this disease can be very high. More than 95% 
of all cancers are registered in women over 40 years old. (Hankey et al., 1994.)   
Besides age, another factor that increases the likelihood of developing breast 
cancer is a woman's genetic predisposition to the disease. During research, it 
was found that probability of occurrence of breast cancer among women with a 
genetic predisposition to the development of the disease may be more than 
20% and, in some cases, increases up to 80%. (Durando et al., 2013).  
2.5.1 GENETICAL PREDISPOSITION 
The vast majority of women do not have an increased predisposition for breast 
cancer. The average woman in the United States has about a 1 in 8, or about 
12%, the risk of developing breast cancer in her lifetime. (Breascancer.org, 
2016).    
But it was found that there are two genes BRCA1 and BRCA2, a mutation 
(change) of which determines the development of the majority of Hereditary 
Breast and Ovarian Cancer (HBOC). (Antoniou et al., 2003).  
It was found in one Australian study that for women who get BRCA1 and 
BRCA2 mutated gene from parents, the overall risk of breast cancer before the 
age of 70 is 40% and only 6% of breast cancer can be caused by these genes 
before the age of 40. (Hopper et al., 1999). 
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3 PURPOSE AND AIM OF THE PROJECT. 
This project task is to create an informative webpage for young women who are 
healthy or diagnosed with primary breast cancer. The aim is to increase 
information about primary breast cancer prevention and treatment options.The 
result will be published as a summary and available at Terveysnetti in English. 
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4 METHODS 
A literature review is an account of what has been published on a topic by 
accredited scholars and researchers. The research question for this literature 
review is: “What information could be useful for young women about breast 
cancer?” 
The author has searched literature in four different databases: CINAHL 
(EBSCOhost), MEDLINE (Ovid), PubMed, Elsevier: Science Direct. The search 
terms that were used: breast cancer, young women, treatment.  
It was decided to take the years of publications of searched articles from 2000-
2015. It was difficult to find recent research articles that would be with free 
access. This was one of the limiters for current research, the another one was 
language. All the publications must have been in English. That is why it was 
also decided to extend the country of publications from Finland first to Nordic 
countries and Europe and then to the whole world because it was difficult to find 
needed research articles published within a specific area. But this idea was also 
good because there are lots of new ways of treatment that were found all over 
the world. And one more inclusion criteria was full-text articles. Inclusion and 
exclusion criteria could be found from Table 1. 
Table 1 
Inclusion criteria Exclusion criteria 
Years of publication 2000-2015 Published before 2000 
Language: English In other language then English 
Full text articles Only abstracts available 
Free in access Access not free 
Studies conducted among young 
women (<50y.o.) and older 
Studies conducted ONLY among 
women >50y.o. 
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Country of publication: all over the 
World 
 
 
After searching all the research articles there were found twenty (n=20) 
matching the search criteria. As you could see from the Table 2.   
 
Database Search items and 
limiters 
Results Selected by 
the title 
Selected by 
the abstract 
Selected 
by  the 
whole text 
CINAHL 
(EBSCOho
st) 
 
Breast cancer and 
young women, 
years: 2000-2015, 
language: English 
5 5 5 3 
MEDLINE 
(Ovid) 
Breast cancer and 
young women, 
years: 2000-2015,  
language: English 
303 30 7 5 
PubMed Breast cancer and 
young women, 
years: 2000-2015,  
language: English 
793 29 14 3 
Elsevier: 
Science 
Direct 
Breast cancer and 
young women, 
years: 2000-2015,  
language: English 
629 29 8 6 
Google  Breast cancer and 
young women, 
years: 1999-2016  
language: English 
8 5 3 3 
Table 2  
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All the rest information and articles author got from official websites of different 
cancer organizations, news and press releases. To get more information on the 
topic author used manual search from search engine Google, using the same 
search terms as previous and some other terms: signs and symptoms, risk 
factors, mammography.  
The author also managed to find through Google some other related research 
articles with more information and free access. That is why it was decided to 
extend the year of publication of searched articles to 1999-2016. They are also 
available in different databases that were used before. 
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5 RESULTS OF THE LITERATURE REVIEW:  
TREATMENT AND PREVENTION 
Fortunately, in most cases, when, after the examination or mammography, 
some changes are found in the mammary glands, they usually do not represent 
any danger. However, in order to verify this, doctors need to conduct additional 
tests. Often for this purpose is chosen an ultrasound test and then biopsy. For 
many women, the referral to a cancer clinic and appointment for biopsy is a lot 
of stress and anxiety. (Tosteson et al., 2014.)  
On the basis of scientific materials that have been studied, the author can say 
that in many cases breast cancer is curable, especially if the disease was 
detected at an early stage of development, and if the treatment was chosen 
based on a number of tumor characteristics (including the extent of its 
distribution, and the presence of metastasis, the sensitivity of cells to estrogen 
and progesterone, HER 2 status, etc.). 
In recent years, significant progress has been made in the treatment and 
diagnosis of cancer. Published in 2013, the results of one study showed that 
83% of women who have been diagnosed with breast cancer, the treatment 
helps to reach the 5-year survival rate (the standard measure for evaluating the 
effectiveness of treatment of cancer).  
Sensitivity of cancer cells to female sex hormones (ER and PR)  
Following histological analysis, which finally allows identifying breast cancer; it 
is possible to determine whether the tumor cells have receptors for the female 
hormones estrogen and progesterone.  
Like many other types of cancer, breast cancer often develops under the action 
of certain hormones. This means that its cells grow faster if they are affected by 
female hormones and slow growth if the action of hormones ceases. 
19 
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Understanding of this helps for the development of a number of new methods of 
treatment and prevention of breast cancer. (Breastcancer.org, 2016.)  
Depending on the case, cancer cells may have a sensitivity to estrogen (ER +), 
progesterone (PR +) or both hormones. Tumors that have receptors (sensitivity) 
to the female sex hormones usually are slowly growing and respond better to 
specific hormonal treatment. (Dunnwald et al., 2007.)   
HER2 Analysis 
Another significant discovery in the treatment of breast cancer is the recognition 
of so-called HER2 proteins and genes that encode their synthesis. HER2 are 
specific proteins that are present on the surface of many normal cells. These 
proteins maintain cell reproduction. The more there are HER2 proteins on the 
cell surface, the faster it grows and divides. (Cancer.net, 2013).   
Development of HER2 proteins is controlled by a particular gene HER2 / neu. It 
was found that about 20% of cancer cells (opposite to normal cells) have a 
plurality of copies of HER2 / neu gene, which allows them to produce more 
protein HER2 and accordingly reproduce faster and more aggressive. (Carney 
et al., 2007.)   
The treatment is selected depending on the histological type of the tumor (i.e., 
from what cells it is composed) from its size and degree of spread (i.e., from its 
stages), the sensitivity of tumor to hormones (ER and PR status) from the 
results of analysis for HER2 and the general state of a women. 
5.1 PREVENTION 
      5.1.1 CHANGE OF LIFESTYLE 
Calcium and vitamin D consumption 
Except for mammography, there are few other preventive measures that could 
be taken to minimize the chance of breast cancer occurrence.  
Some studies have shown that regular physical activity (e.g., at least 2.5 hours 
of brisk walking or jogging per week), decreasing of body weight into the normal 
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range and avoiding the consumption of alcoholic beverages may partly reduce 
the likelihood of developing cancer, even in women with a genetic 
predisposition to developing this disease. (Hashemi et al., 2014 and 
Widschwendter et al., 2015.)  
Based on the results of studies it is suggested that for women who get enough 
calcium and vitamin D the risk of developing breast cancer may be lower than 
the average. (Cui and Rohan, 2006.)  
 
5.1.2 RISK-REDUCING MASTECTOMY 
Early mastectomy is the removal of both breasts that reduces the likelihood of 
developing cancer by more than 90%. And more women with high risk of breast 
cancer are opting for this operation.  
Currently, such an operation is recommended for: 
 Women with a proven mutation in the BRCA genes 
 Women with a strong family history of breast cancer 
 Women with lobular carcinoma in situ, either lobular or ductal hyperplasia 
(Hartmann at al., 1999.)  
 
5.1.3 OOPHORECTOMY  
Oophorectomy is called in other words the removal of ovaries. For women who 
have not yet reached menopause and have mutations in the BRCA1 or BRCA2 
genes for prevention of breast cancer and ovarian cancer, it is recommended to 
surgical remove both ovaries and fallopian tubes. After this operation, the 
probability of developing breast cancer is reduced by 56% and the likelihood of 
ovarian cancer by 79%. (Gardner, 2010.)  
 
5.2 TREATMENT OPTIONS 
      5.2.1 SURGERY 
In order to remove the tumor, depending on the case, surgery may be 
recommended, during which the mammary gland is completely removed (this is 
so called mastectomy) or an operation during which only the tumor is removed 
(lumpectomy). In cases where there is a high risk of cancer in the second breast 
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(or if it has already spread there), it can be recommended to remove both 
breasts at the same time. During surgery, lymph nodes into which a tumor has 
spread are also removed.  In cases where only the tumor is removed, but not 
the breast completely, after the operation radiotherapy is almost always 
performed. (Cancer Research UK, 2014.)  
In many cases, immediately after removal of the tumor, doctors can establish a 
temporary artificial implant that will correct a cosmetic defect. Such implants do 
not increase the likelihood of developing breast cancer, and over time it is 
possible to replace them with long-term implants, which completely restore 
breast shape. (ACS, 2016.)  
5.2.2 RADIOTHERAPY 
Radiation therapy is used to irradiate the area where the tumor was, and kill 
cancer cells with X-rays. Radiotherapy is usually prescribed in those cases 
when during the operation the only tumor is removed, but not the whole breast, 
or when the tumors could spread to the lymph nodes or other organs. (Cancer 
Research UK, 2014.)  
Intensity Modulated Radio Therapy (IMRT) uses linear accelerators to deliver 
radiation to the tumor. (Radiologyinfo.org, 2015).  
Tomotherapy is another approach of IMRT it uses a different treatment planning 
system. It is a new way of delivering radiotherapy in which 3D imaging tools (CT 
and MRI) are used to create a vision of tumor and decide on the strength of 
radiation. It helps to make the treatment more precise and keep away from 
lungs and heart the high dosage of radiation. (Jacob et al., 2012 and Cancer 
Treatment Centers of America, 2016.)  
CyberKnife used in a pilot study of University Medical Center Utrecht and 
Philips a new kind of treatment which is called   MR-guided High-Intensity 
Focused Ultrasound (MR-HIFU). The technology is developed in Helsinki, 
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Finland, by the team lead by Falko Busse, General Manager MR-Therapy at 
Philips Healthcare. This machine is destroying small size tumors by heating 
them up to 65°C without making any incisions. This procedure is performed 
inside the MRI so that the tumor is seen in real-time and settings could be 
changed. (Philips, 2012.)  
5.2.3 CHEMOTHERAPY 
Chemotherapy is the treatment with help of drugs capable of inhibiting the 
division of cancer cells or destroying them. In breast cancer, doctors may 
suggest taking chemotherapy drugs as tablets or as intravenous lines. Usually, 
chemotherapy is carried out in cycles. A full course of treatment consists of 
several cycles and can take several months. 
When the prescribed chemotherapy is after the operation, it is called "adjuvant". 
Such treatment is needed to kill cancer cells that may remain in women after 
surgery. This treatment helps to prevent the recurrence of lumps and destroy 
tumor metastasis. (Burstein et al., 2014.)  
When the prescribed chemotherapy is before the surgery, it is called 
"neoadjuvant". The main purpose of this treatment is usually to reduce tumor 
size and make it easier to remove it during the surgery. If doctors determine that 
the tumor did not decrease under the influence of this treatment, they will be 
able to plan the use of other medications.  
5.2.4 TARGET THERAPY 
Target therapy is a new method of breast cancer treatment that uses drugs 
blocking the protein HER2. These drugs are different from drugs that are used 
for chemotherapy and they tend to have fewer side effects. (Carney et al., 
2007.)   
Essential drugs, which are used for Target therapy, are trastuzumab 
(Trastuzumab) and pertuzumab (Pertuzumab). They are proved to be a better 
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combination of medication for breast cancer and have efficacy and safety profile 
(Managala et al., 2011.) They are attached to the protein HER2, blocking its 
work and thereby reduce the rate of growth of cancer cells. It is assumed that 
these drugs also help the cells of the immune system to destroy cancer cells. 
(Cancer.net, 2016.)  
Trastuzumab is administered by intravenous injection (1 time per week or 1 
every 3 weeks). The course of treatment lasts 1 year. Depending on the case, 
the treatment can be commenced preoperatively or postoperatively and may be 
combined with chemotherapy. This treatment increases the effectiveness of 
treatment for breast cancer and reduces the likelihood of the recurrence of the 
tumor. (Lin and Rugo, 2007.)  
 
5.2.5 HORMONE THERAPY 
If the tests show that cancer cells have receptors for the female sex hormones 
estrogen (ER +) and progesterone (PR +), after the completion of the basic 
course of treatment, the treatment with special drugs is offered for the patient, 
which block these hormones. This is called hormonal treatment of breast 
cancer. There are two types: estradiol-only (ET) and estrogen-progesterone 
(EPT). Hormonal therapy helps to reduce the risk of mortality and risk of 
reoccurrence of breast cancer. (Mikkola et al., 2016 and Cancer.net, 2016.)  
Tamoxifen is one example of the most common drugs used for chemoherapy. It 
blocks the action of female sex hormones on breast tissue. It is used in both 
ways for prevention and treatment. 
This drug blocks estrogen receptors in breast cells, including cancer cells, but 
stimulates the estrogen receptors in the uterus and in bones. During the 
research, it was found that in women with a high risk of developing cancer who 
take tamoxifen for 5 years, the probability of developing tumors can be reduced 
by 45% or even more. Unfortunately, tamoxifen may cause unpleasant and very 
serious side effects. Therefore, this drug should be surely checked with the 
doctor. (Nazarali and Narod, 2014.) 
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Another example of drugs used in chemotherapy is aromatase inhibitors 
(letrozole, anastrozole, exemestane). These drugs block estrogen production in 
fatty tissue and are used only for the treatment of women during menopause. 
Like tamoxifen, they reduce the likelihood of the recurrence of cancer. They can 
be used in conjunction with tamoxifen and this improves the efficiency of 
treatment. (Breastcancer.org, 2016.)  
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6 CASE EXAMPLE 
This case example is created by the author and based on the literature. It would 
help readers to understand better how the treatment process works. 
A woman 35 y.o. was diagnosed with breast cancer. After different analysis it 
was found that tumor has stage 2A. This means that tumor is greater than 2 cm 
but  less than 5 cm in diameter and has not spread to lymph nodes or other 
organs. Tumor has also receptors to the female sex hormones (ER+) and has 
HER2/neu genes, which means the cancer is aggressive. 
After consultation with the doctor it was decided to save the breast. This means 
patient has made a choice for lumpectomy (only tumor removal). There for the 
treatment process starts with chemotherapy, which is called “neoadjuvant”. This 
means it is done before the operation. The purpose of it is to reduce the size of 
tumor to make it easier to reduce during the surgery. One cycle of 
chemotherapy would take a couple of months. 
Following chemotherapy is the surgery (lumpectomy). During which the tumor is 
removed. During the same surgery doctor establishes temporary artificial 
implant that will correct a cosmetic defect. This was agreed with the patient 
before the operation during consultation. Surgery is done during one day. 
After surgery again course of chemotherapy starts but now it is called 
“adjuvant”, because it is used after surgery. It also helps to prevent 
reoccurrence of lumps. It is advised to have some breaks between the courses, 
so it will take several months. Together with chemotherapy is used target 
therapy. Combination of drugs (trastuzumab and pertuzumab) is used. They 
block protein HER2 and prevent growth of cancer cells and reduce the 
likelihood of reoccurrence of tumor. The course of this treatment lasts 1 year. 
When course of chemotherapy is finished, radiotherapy starts. When there is a 
possibility that not all cancer cells were removed during surgery it helps to ”kill” 
those cancerous cells. Radiotherapy corse takes about couple of months.  
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Hormonal treatment is used in patients who have cancer with hormonal 
sensitivity, when the main course of treatment is finished. So now, the patient is 
proposed to start hormonal treatment, because previously it was known that 
tumor has receptors for estrogen only ER+. She will use estradion-only 
hormonal treatment. The most common drug for this treatment which blocks 
estrogen receptors in breast cells is Tamoxifen. It should be taken during 5 
years, and then the risk of developing new tumors in breast will be reduced by 
45%. 
Treatment process and full recovery takes a long time and a very important role 
has personal attitude of the patient towards this disease. Positive thinking, 
intention for positive results and faster recovery helps to ease the main process 
of treatment and achieve better results. 
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7 EMPIRICAL IMPLICATION 
This project task was to create an informative web page about breast cancer 
treatment and prevention options. The page is ready and could be found on 
Terveysnetti. It was decided to put information there, so that it could be also 
printed out as a paper version. There are all the important aspects of breast 
cancer and for more information there is also a reference to self-palpation video 
instructions from YouTube.  
The process of this thesis started in January 2016. The topic was chosen and 
the search of articles started. Few related articles were found and then the 
project plan was done by February. After a long gap in writing process, author 
started the search of articles again in August 2016. Then the writing process 
started. Presentation of this thesis was on 12 December 2016. The web page 
was also created by this time and is available in Terveysnetti pages online. 
The author succeeded to get as much as possible needed information for young 
women of breast cancer. She also managed to put information in easy and 
understandable words. The gap in writing was not a good idea; it was difficult to 
get back to work after it. 
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8 DISCUSSION 
The focus of this thesis is based on theoretical framework collected from 
research articles. 
Lack of information could influence patient's decision making about the 
treatment of breast cancer. The importance is based on the need of information 
for young women diagnosed with primary breast cancer on different treatment 
options and also information for healthy women. It also includes different new 
ways of treatment, survival rates, and explanation. All these aspects of the 
disease can affect on patients' decision making about the treatment process 
and explain the importance of the role of healthcare professionals’ participation. 
Reliability and limitations 
The author tried to find the most recent research articles and recommendations 
for this thesis. All the sources are official, recommendations that were found are 
from official governmental and non-governmental organizations that specify on 
cancer in general and breast cancer specifically. So, information gathered from 
the articles used for this review is reliable.  
But this project is done without any funding, so the limitation was the fact that 
most recent articles do not have free access, due to this fact information 
collected from articles could be a little bit old and actual figures about statics 
and survival rate could be even higher at the moment. 
The other limitation could be the fact that this review was written only by one 
author, and there is no another view presented on this topic. As well as, there is 
no conflict of interest.   
This is not a new topic for research. The author has found some earlier 
research articles that have similar kind of topic but with different aspects. 
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Information from research articles was collected and critically appraised to the 
research question. Some of the studies about new treatment options that were 
found do not have conclusion data because they are still in process.  
Critical appraisal questions that were used are taken from the article ” How to 
Critically Appraise an Article” written by Young and Solomon (2009). These are 
ten important questions which were used: 
1. Is the study question relevant? 
 
2. Does the study add anything new? 
 
3. What type of research question is being asked? 
 
4. Was the study design appropriate for the research question? 
 
5. Did the study methods address the most important potential sources of 
bias? 
 
6. Was the study performed according to the original protocol? 
 
7. Does the study test a stated hypothesis? 
 
8. Were the statistical analyses performed correctly? 
 
9. Do the data justify the conclusions? 
 
10. Are there any conflicts of interest? 
 
 
 
 
 
 
30 
 
TURUN AMK:N OPINNÄYTETYÖ | Anzhelika Mitsuk  
9 CONCLUSION 
Frightening messages about breast cancer, especially about how many women 
die annually from the disease and about how insidious it can be does not 
always motivate women to action. Sometimes it makes a person to give up and 
accept the challenge that can actually be solved. Therefore, the focus of this 
thesis is on what women can do to take care of their health.  
Preventive measures may be part of a natural concern about health and well-
being of loved ones, a simple but effective way to avoid serious problems in the 
future and live a happy life. 
Improving Breast screening service is an important area of women's health, as 
the prevalence of breast cancer and increased mortality define extreme urgency 
of early detection of this disease. In most cases, it relates to women of 
childbearing age, occupying the most active vital position in social production. 
Conducted earlier surveys, which were limited to inspection and palpation of the 
mammary glands, were associated with significant rate (up to 39%) diagnostic 
errors. The frequency of detection at stage I did not exceed 23-29% of all 
cases, resulting in unnecessarily a large number of surgical interventions for 
diagnostic purposes.  
Despite the fact that mammography screening can give false-positive results it 
is still very useful and important for breast cancer detection. Because the earlier 
it is detected the better chances there are for rehabilitation and returning back 
to normal life for women.  
Of course, it is a big issue when somebody gets a diagnosis of breast cancer. It 
affects women state in general; anxiety and stress are very common in this 
situation. This can be caused also because of lack of information about breast 
cancer and its treatment process. It can also cause difficulty with decision 
making and choose the better treatment option. That's why the author of this 
literature review collected information on different treatment options available 
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and also some new treatments that are in process of study for breast cancer, 
and described some difficult terms and gathered general information known 
about this disease. 
This information would be also useful for healthy women, who don’t even think 
they could have breast cancer.  
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APPENDIX 
Statistics from WHO: http://globocan.iarc.fr/Pages/fact_sheets_cancer.aspx  
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